© 2022 MJH Life Sciences and Cancer Network. All rights reserved.
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Experts discuss use of ponatinib in chronic myeloid leukemia and optimal dosing.
February 17th 2022
Jorge E. Cortes, MD, presents data from a dose ranging study of ponatinib in patients with chronic-phase chronic myeloid leukemia.
Hematologic oncologists summarize the dose ranging study of ponatinib in patients with CML and discuss clinical implications of this work.
February 24th 2022
Dr. Cortes reviews ponatinib dosing strategies based on patient profiles and mutational status.
Hagop Kantarjian, MD responds to a review of dosing options in patients with CML treated with ponatinib.
March 3rd 2022
Jorge E. Cortes, MD and Hagop Kantarjian, MD debate optimal dosing and discuss how they use ponatinib in patients with CML.
Experts review future implications such as using ponatinib in earlier lines of therapy and in patients with Ph-positive ALL.
March 10th 2022
Jorge E. Cortes, MD and Hagop Kantarjian, MD share a summary on ponatinib in CML and ALL and exploration of potential future studies.
May 27th 2022